Therapeutic complement targeting in ANCA-associated vasculitides and thrombotic microangiopathy by Novikov, P. et al.
 © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Review 
 Biomed Hub 2016;1:453106 ( DOI: 10.1159/000453106 ) 
 Therapeutic Complement Targeting 
in ANCA-Associated Vasculitides and 
Thrombotic Microangiopathy 
 Pavel Novikov a    Natalia Kozlovskaya a    Sergey Moiseev a    Eugene Shilov a    
Irina Bobkova a    Adrian Schreiber b, c    Dmitry Tsvetkov b, c    Maik Gollasch b–d    
Nancy Mah e    Khadija El Amrani e    Andreas Kurtz e  
 a  I.M. Sechenov First Moscow State Medical University,  Moscow , Russia;  b  Experimental and 
Clinical Research Center, a Joint Cooperation between the Charité Medical Faculty and the 
Max Delbrück Center for Molecular Medicine at the Charité and the Max Delbrück Center for 
Molecular Medicine in the Helmholtz Association,  c  Nephrology and Intensive Care Medicine,
Campus Virchow, and  d  Koch Metchnikoff Forum, Section Nephrology, and  e  Berlin-Brandenburg
Center for Regenerative Therapies (BCRT), Charité – Universitätsmedizin Berlin,  Berlin , Germany 
 Keywords 
 ANCA-associated vasculitis · C5b-9 · Opsonins · CCX168 · C5a receptor · Human pluripotent 
stem cells · Genetic testing · Complement 
 Abstract 
 Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of 
systemic autoimmune disorders characterized by necrotizing inflammation of medium-to-
small vessels, a relative paucity of immune deposits, and an association with detectable cir-
culating ANCAs. AAVs include granulomatosis with polyangiitis (renamed from Wegener’s 
granulomatosis), microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis 
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 What Is It about? 
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are systemic auto-
immune diseases of medium-to-small vessels. Recent findings predominantly from animal studies 
showed a crucial role of the complement system in the pathogenesis of AAVs, which had previously 
been demonstrated only for thrombotic microangiopathy (TMA). Following a multidisciplinary 
approach, we argue that therapies directed against the complement system point to the necessity of a 
genetic workup of genes of complement components and regulators in patients with AAV and TMA. We 
conclude that genetic testing together with pluripotent stem cells and bioinformatics tools may broaden 
our approach to the treatment of patients with aggressive forms of AAVs.
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(Churg-Strauss syndrome). Until recently, AAVs have not been viewed as complement-medi-
ated disorders. However, recent findings predominantly from animal studies demonstrated a 
crucial role of the complement system in the pathogenesis of AAVs. Complement activation 
or defects in its regulation have been described in an increasing number of acquired or ge-
netically driven forms of thrombotic microangiopathy. Coinciding with this expanding spec-
trum of complement-mediated diseases, the question arises as to which AAV patients might 
benefit from a complement-targeted therapy. Therapies directed against the complement 
system point to the necessity of a genetic workup of genes of complement components and 
regulators in patients with AAV. Genetic testing together with pluripotent stem cells and bio-
informatics tools may broaden our approach to the treatment of patients with aggressive 
forms of AAV.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are 
systemic disorders with characteristic features of necrotizing inflammation of small and 
medium vessels. AAVs comprise several clinically and pathologically defined disease entities: 
(1) granulomatosis with polyangiitis (renamed from Wegener’s granulomatosis), mainly 
associated with ANCA against proteinase 3 (PR3); (2) microscopic polyangiitis, mainly asso-
ciated with ANCA against myeloperoxidase (MPO); (3) eosinophilic granulomatosis with 
polyangiitis (renamed from Churg-Strauss syndrome); and (4) renal-limited pauci-immune 
necrotizing and crescentic glomerulonephritis  [1] . AAVs are primarily caused by leukocyte 
migration and subsequent tissue damage. Although it is clear that genetic and environmental 
factors are involved, the pathophysiological mechanisms behind AAVs are still not fully 
understood despite decades of research.
 The Complement System in Experimental AAV 
 ANCAs are directed against the granule proteins MPO or PR3, and there is evidence from 
animal and in vitro studies that ANCAs are pathogenic and cause effector functions in neutro-
phils and monocytes, leading to subsequent tissue damage  [2, 3] . Binding of ANCA IgG to 
membrane-expressed ANCA antigens on the surface of preactivated neutrophils (primed) 
leads to full activation of these cells, resulting in degranulation of tissue-damaging proteases, 
generation of reactive oxygen species, generation of inflammatory cytokines such as IL-1β, 
and generation of neutrophil extracellular traps.
 Until recently, AAVs have not been viewed as a complement-mediated disease. However, 
increasing data predominantly from animal studies have demonstrated a crucial role of the 
complement system in the pathogenesis of AAV. The first animal study using a passive 
anti-MPO antibody transfer model showed that mice deficient in either complement factor 
B or complement component C5 were protected from disease, whereas complement 
component C4-deficient mice developed disease comparable to wild-type mice. These 
results suggested a central role for the alternative pathway of complement activation, 
whereas the classic or lectin-binding pathway is apparently not involved  [4] . In a different 
study, anti-MPO necrotizing and crescentic glomerulonephritis could be blocked by treating 
mice with a C5-inhibiting monoclonal antibody  [5] . However, it is still unclear as to which 
tissue-damaging mechanism of the complement system is involved in the pathogenesis of 
AAV.
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 In general, the complement system could potentially mediate AAV disease via 3 different 
mechanisms: (1) a direct tissue-damaging effect by generation of C5b-9 (the terminal 
membrane attack complex [MAC]); (2) generation of opsonins (C3b, iC3b, and C3d), which 
decorate target surfaces through covalent surface binding to favor removal of target struc-
tures; or (3) generation of anaphylatoxins (C3a and C5a), which are potent proinflammatory 
molecules that attract and activate leukocytes through interaction with their receptors C3aR 
and C5aR. In a follow-up study, our group tested the hypothesis that the complement system 
mediates its action in AAV by generation of anaphylatoxins; in a murine anti-MPO animal 
model, C5aR-deficient mice were almost completely protected from anti-MPO-induced 
disease  [6] . Furthermore, we could demonstrate that ANCA-stimulated neutrophils release 
unidentified substances that activate the complement system with generation of C5a ( Fig. 1 ). 
Recently, this work was confirmed in transgenic mice expressing human C5aR, where a 
specific small-molecule blocker of human C5aR (CCX168) reduced disease in an anti-MPO 
model  [7] . It is conceivable that C5a, generated with activation of the complement system, 
binds to its cognate C5aR expressed on the neutrophil’s surface, which in turn preactivates 
(“primes”) the neutrophil for further ANCA IgG activation.
 Together, these studies imply an important role of the complement system in the patho-
genesis of AAVs. At first glance this is surprising, since complement activation or defects in 
its regulation have been identified and well appreciated in an increasing number of acquired 
or genetically driven forms of thrombotic microangiopathy (TMA), which exhibit clinical and 
histopathological features distinct from those of AAV. However, a subgroup of patients with 
AAV displays histologic signs of TMA, which is associated with low C3 levels and poor renal 
prognosis  [8] . This could further support the idea of a significant overlap between the AAV 
and TMA disease entities.
 Fig. 1. Complement in anti-neu-
trophil cytoplasmic antibody 
(ANCA)-associated vasculitis. I. 
Cytokine-primed neutrophil 
granulocytes are activated by 
binding of ANCA IgG to surface-
expressed ANCA antigens. II. This 
process leads to full activation, re-
sulting in the release of ROS and 
proteases. III. The alternative 
pathway of complement activa-
tion is activated, leading to gen-
eration of the C5-convertase com-
plex (C3b Bb P). IV. The potent 
anaphylatoxin C5a is generated, 
which binds to its receptor, C5aR 
(V.) expressed on the neutrophil 
surface, leading to further neutro-
phil activation as an amplification 
loop. 
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 Complement in Human TMAs 
 Complement-mediated atypical hemolytic uremic syndrome (aHUS) results from dysregu-
lation of endothelium-anchored complement activation. This activation results in endothelial 
damage and platelet activation, which occurs in approximately 90% of cases of aHUS  [9] . The 
discovery of ADAMTS13, a zinc-containing metalloprotease enzyme that cleaves von Willebrand 
factor, has permitted a more accurate diagnosis of thrombotic thrombocytopenic purpura (TTP) 
and an appreciation of overlapping clinical features of TTP and aHUS  [9] . While ADAMTS13 defi-
ciency causes TTP, partial ADAMTS13 deficiency is a common finding in aHUS patients, which 
warrants genetic screening and functional tests of ADAMTS13 in aHUS patients  [10] .
 The alternate complement pathway is continuously active, albeit at a low level. Disturbed 
function or deficiency of complement regulatory proteins of the alternate pathway leads to 
continuous generation of C3 and C5 convertases, resulting in formation of the MAC ( Fig. 1 ). 
The MAC induces lysis of endothelial cells or damage at the site of the endothelium and 
platelets, which results in TMA in certain vascular beds that are more prone to this injury than 
others  [11–14] . Mutations in genes encoding for complement factor H ( CFH ), complement 
factor I ( CFI ), complement factor B ( CFB ), membrane cofactor protein ( MCP )/CD46, and  C3 
comprise about 50% of the known mutations in patients with aHUS  [13, 15] . Another 10% of 
aHUS is due to autoantibodies to complement factor H. In about 10–12% of patients with aHUS, 
combined mutations of  CFH ,  CFI ,  MCP ,  C3 ,  CFB , or thrombomodulin ( THBD ) may exist  [13] .
 In general, patients with aHUS have a poor prognosis. Thromboses can occur almost 
everywhere, but smaller blood vessels in the kidneys, lungs, brain, gastrointestinal system, or 
heart are often involved. More than 60% of patients with mutations of  CFH ,  CFI ,  C3 ,  CFB , and 
 THBD either die or develop end-stage renal disease within 1 year of presentation  [16] . Patients 
with  MCP mutations have a better long-term outcome, with only 30% progressing to end-
stage renal disease, though they tend to have a disease course with frequent relapses  [17] .
 Plasma exchange therapy is the first-line therapy for children with aHUS. Although 
plasma infusion replenishes deficient complement regulators, plasma exchange has the 
added benefit of removing mutant complement factors and/or autoantibodies  [13, 18] . The 
rate of remission after plasma exchange is variable, depending on the genetic mutations  [13] . 
Plasma exchange is of little benefit to patients with an  MCP mutation, as MCP is a transmem-
brane glycoprotein and no circulating factor  [13] . Immunosuppressive agents are of no 
benefit in aHUS, except to patients with CFH autoantibodies  [13] . Eculizumab is a monoclonal 
antibody to C5 that prevents cleavage of C5 to C5b, thus preventing formation of the MAC 
( Fig. 1 ). Eculizumab has been used in patients with aHUS with favorable results  [19, 20] . 
There is a high recurrence rate of aHUS after renal transplantation, which is dependent on the 
genetic mutation. There is an increased risk of aHUS recurrence in patients with mutations of 
 CFH ,  CFI , and  C3 , whereas the risk is lower for patients with  MCP mutations  [13] . Of note, there 
is an increased risk for donors of developing aHUS, as they might have disease-causing muta-
tions with incomplete penetrance  [13] . Thus, if living related kidney transplantation is the 
only option available to a family, then the donor and the recipient should undergo a thorough 
genetic evaluation of the complement system, and the donor should be counseled that even 
if the genetic test is negative, the risk of developing aHUS is not completely eliminated  [13] .
 Thus, genetic screening for aHUS susceptibility factors is well appreciated to help clarify 
whether a TMA present in a complement-amplifying condition arises from unmasking a 
genetically driven aHUS, versus a time-limited complement storm-mediated aHUS due to 
direct endothelial damage in which no genetic predisposition is present  [9] . Therefore, a 
precise molecular diagnosis may help in treating patients with TMA. Clinical use of massively 
parallel DNA sequencing will provide a way to identify genetic variants in the complement 
system to better diagnose patients. Although exciting, these advancements are not without 
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limitations. Massively parallel sequencing (next-generation sequencing) platforms provide 
vast quantities of data, but the associated error rates (approx. 0.1–15%) are higher – and the 
read lengths are generally shorter (35–700 bp for short-read approaches) – than those of 
traditional Sanger sequencing platforms, requiring careful examination of the results and 
possibly combined approaches with both technologies, particularly for variant discovery and 
clinical applications  [21, 22] .
 The Complement System in Human AAV 
 Complement Activation in Human AAV 
 Chen et al.  [23] investigated the signs of complement activation in renal biopsy spec-
imens of 7 patients with MPO-ANCA-associated pauci-immune glomerulonephritis. The MAC, 
C3d, factor B, and factor P could be detected in glomeruli and small blood vessels of patients 
with AAV, while they were absent or scarce in patients with minimal change disease and 
normal renal tissue. Systemic activation of complement by the alternative pathway was also 
found in 120 patients with AAV who were distributed into 2 groups based on the presence or 
absence of active inflammation. Plasma levels of C3a, C5a, soluble C5b-9, and Bb were signif-
icantly higher in active AAV than in remission of vasculitis, while plasma levels of properdin 
were significantly lower in patients in the active stage of disease  [24] . Moreover, deposition 
of Bb – an alternative complement pathway marker – in glomeruli correlated with the 
proportion of total crescents, the extent of interstitial infiltrate, interstitial fibrosis, and 
tubular atrophy. Urinary levels of Bb, C3a, C5a, and soluble C5b-9 were significantly higher in 
active AAV than in the stage of remission. Urinary levels of Bb in patients with active AAV 
correlated with serum creatinine levels  [24] . In a recent study, C3d, C4d, and C5b-9 staining 
was found to be positive in a majority of renal biopsies analyzed. C3d and properdin staining 
was associated with cellular crescents  [25] .
 These findings provide additional evidence that complement activation through the 
alternative pathway contributes to the development of AAV ( Fig. 2 ). C5a plays a major role, 
as it shows strong chemoattraction to neutrophils and is able to prime those cells, thus 
enabling their full activation by ANCA  [4] .
 Genetic Susceptibility to Human AAV 
 To improve the understanding of genetic factors involved in human AAVs, genetic compo-
nents have been investigated in candidate association studies and 2 genome-wide association 
studies (GWAS). The majority of the identified genetic AAV risk factors are common variants 
( Fig. 2 ). The genes include  CTLA4 ,  PTPN22 ,  COL11A2 ,  SERPINA1 , and the major histocompat-
ibility complex class II gene cluster  [26–29] .
 A recent meta-analysis determined genetic variants most likely associated with AAV. The 
study also investigated whether diagnostic and serological subtypes within AAV have distinct 
genetic backgrounds  [30] . The authors identified 33 genetic variants associated with AAV. 
These genetic variants were in or near the following genes:  CD226 ,  CTLA4 ,  FCGR2A ,  HLA-B , 
 HLA-DP ,  HLA-DQ ,  HLA-DR ,  HSD17B8 ,  IRF5 ,  PTPN22 ,  RING1/RXRB ,  RXRB ,  STAT4 ,  SERPINA1 , 
and  TLR9 . The authors found that in 76% of the genetic variants, a subdivision based on ANCA 
serotype resulted in higher odds ratios than a subdivision based on clinical diagnosis. The 
results indicated that a subdivision of AAV based on ANCA serotype has a stronger genetic 
basis than a subdivision based on clinical diagnosis  [30] . It is important to note that GWAS 
identify specific DNA locations, not complete genes. Many variants identified in GWAS are 
nowhere near genes encoding proteins. It is intriguing to speculate that some of the locations 
could affect complement regulatory mechanisms. In support, Persson et al.  [31] found that 
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the allotype frequency of C4A3 among patients with ANCA-positive small vessel vasculitis 
was increased, and that there was an increase in the C3F allele in patients with PR3-ANCA-
negative but not MPO AAV in a British cohort. The authors suggested that genetic factors and 
the complement system may be of importance in development of the disease, and that these 
results should increase the interest in studying the complement system in ANCA-associated 
small vessel vasculitis.
 Together, the results point to the necessity of a complete genetic workup of genes of 
complement components and regulators in patients with AAV and to the importance of a 
functional characterization of potential pathogenic variants.
 Complement as a Target for Treatment in Human AAV 
 The oral blocker of the C5aR CCX168 was evaluated in a phase II multicenter clinical trial 
on AAV patients (NCT02222155). The CLEAR study was designed to assess whether high-
 Fig. 2. Pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs). In a 
(genetically) susceptible individual who is exposed to an environmental trigger, such as  Staphylococcus au-
reus , antigen-presenting cells (APCs) result in the proliferation of T-helper (TH; TH-17) cells. These activated 
T cells activate macrophages and attract neutrophils. Macrophages release the proinflammatory cytokines 
IL-1β and tumor necrosis factor-α (TNF-α), both of which prime neutrophils to display myeloperoxidase 
(MPO) and proteinase 3 (PR3). APCs process and present these antigens to TH cells, and chronically acti-
vated TH cells form effector memory T cells, which then form granulomata. TH cells activate B cells that re-
lease ANCAs of the immunoglobulin G type into the bloodstream. In addition, the number of regulatory T cells 
is likely reduced and their function impaired, allowing for persistent or enhanced B-cell activation. Circulat-
ing primed neutrophils become activated by ANCAs following binding to both Fcγ and Fab2. Degranulation 
of bound neutrophils leads to further neutrophil recruitment to the site and to release of reactive oxygen 
species (ROS) and neutrophil extracellular traps, leading to endothelial cell damage and inflammation. 
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dose chronic steroids used in the standard-of-care (SOC) regimen for AAV could be reduced 
or eliminated – without compromising efficacy – by replacement with CCX168. The CLEAR 
trial met its primary endpoint based on Birmingham Vasculitis Activity Score (BVAS) response 
at week 12: the proportion of patients with a BVAS response at week 12 was numerically 
superior and statistically noninferior among patients receiving CCX168 plus low-dose steroids 
and no steroids as compared to the high-dose steroid-treated SOC group (86, 81, and 70%, 
respectively). The mean percent changes in BVAS from baseline to week 12 were 79, 73, and 
57% in the 3 groups, respectively. A higher proportion of patients receiving CCX168 had early 
clinical remission at week 4, sustained through week 12. At 4 weeks, there was a 47% decrease 
in albuminuria in patients receiving CCX168 without steroids ( p = 0.0006 vs. SOC), and a 40% 
decrease in patients receiving CCX168 plus low-dose steroids ( p = 0.003 vs. SOC), but an 
increase of 15% in patients from the control groups. At 12 weeks, the change from baseline 
was –56, –44, and –21% in the 3 groups, respectively. Patients receiving CCX168 (especially 
without steroids) showed a significant improvement in health-related quality of life domains 
such as physical functioning, mental health, emotional well-being, pain, and vitality. Esti-
mated glomerular filtration rates improved similarly with CCX168 compared to controls, 
indicating that steroids are not needed to improve renal function when patients are taking 
CCX168. CCX168 appeared to be well tolerated by patients with AAV (http://ir.chemocentryx.
com/releasedetail.cfm?ReleaseID = 972372). The North American CLASSIC trial is evaluating 
the safety of 10 or 30 mg of CCX168 twice daily for 12 weeks when added to the full-dose 
corticosteroid SOC regimen plus cyclophosphamide or rituximab. The CLASSIC safety study 
met its objectives. The addition of CCX168 to the current SOC therapy did not add safety 
concerns beyond those seen with SOC alone. The incidence of serious adverse events was 
similar across the treatment groups in the study (http://ir.chemocentryx.com/releasedetail.
cfm?ReleaseID = 976002). ChemoCentryx plans to advance CCX168 into phase III devel-
opment for AAV.
 Taken together there are reliable experimental animal data and data from human marker 
studies to support the notion that the complement system plays a pathogenic role in AAV. 
However, further studies are needed to understand exactly how the complement system is 
activated.
 Innovative Approaches to Disease Modeling and Outcome Prediction 
 General Considerations 
 Human induced pluripotent stem cells (hiPSCs) are donor-specific cell lines which have 
the capacity to differentiate in all cell types of the human body. They are excellent candidates 
for individualized disease modeling, as well as for applications in precision medicine. The 
cells provide the starting material for advanced therapeutic products for clinical use in tissue 
repair and regeneration. Here, we present an outlook on the use of iPSCs for the modeling of 
renal diseases and the derivation of cell types from iPSCs which could be applicable in kidney 
repair. The use of bioinformatics tools and cell-related databases to understand the disease 
on the cellular level will be described as well.
 PSCs for Modeling and Repair of the Kidney 
 The kidney is a complex organ with at least 26 different cell types and an intricate 
anatomical structure necessary to facilitate regulation of homeostasis, electrolyte concentra-
tions, the extracellular fluid volume, and blood pressure. After birth, the human kidney has 
almost no ability to regenerate. Repair is limited to cases of acute kidney injury, but whether 
repair occurs is not predictable; moreover, the endogenous capacity for repair of acute 
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damage declines over time. The interplay of the different cell types in chronic and acute 
disease progression in human patients is not completely understood, and hence the role of 
different cell types during degeneration and repair remains unclear.
 hPSCs are able to differentiate into all cell types of the human body. With the development 
of reprogramming technology  [32] , it became possible to derive hiPSCs from any person. This 
created the opportunity to derive any renal cell type from human donors. Since hiPSCs are 
genetically identical to the donors, they provide a basis for modeling kidney disease on an indi-
vidual level and for cell-based therapies. At the Berlin-Brandenburg Center for Regenerative 
Therapies (BCRT), we were able to differentiate hiPSCs into the major precursor cell types of 
the human metanephros: metanephric mesenchyme and ureteric bud epithelial cells. Moreover, 
we could differentiate these cells further into different mature renal cell types, including podo-
cytes, mesangial cells, proximal and distal tubular epithelial cells, and collecting duct epithelial 
cells. In addition, we were able to derive human kidney organoids at the renal vesicle stage, 
providing a 3-dimensional model of kidney organogenesis and the kidney ( Fig. 3 ). These 
findings allow us now to investigate the applicability of the different cell types to cell-based 
therapies of chronic and acute kidney disease  [33] . In addition, the option of differentiating 
different renal cell types from iPSCs allows us to analyze disease phenotypes not only on the 
cellular level but also on an individual basis. In addition, interactions of different renal cell 
 Fig. 3. Human induced pluripotent stem cells (iPSCs) will be derived from defined cohorts of patients who 
have been characterized by omics technologies and for whom, for example, genotype-phenotype/disease as-
sociations have been found. There is a clear need to validate the functional implications of this association 
for safe translation into precision medicine. Human iPSC banks will be established from these cohorts to pro-
vide a widely usable resource of patient surrogates for these validation studies, which can be used not only 
for renal diseases. The human iPSCs will be generated in a dedicated iPSC core facility. For the kidney, we 
established the basis for diverse model systems by deriving renal organoids and renal cell types from human 
iPSCs. In addition, we use and are developing bioinformatics tools and databanks to assess cell- and tissue-
related data for their comparability with the iPSC-derived cell lines and model systems. 
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types – or between renal cells and hiPSC-derived cells of other organs such as hepatocytes or 
variants of the complement system – can now be assessed in vitro on a patient-specific level. 
Furthermore, by genetically modifying the cells, it is possible to elucidate the effect of genes 
and specific mutations on disease progression or on drug responsiveness.
 It is thus possible to verify in vitro the association between a patient’s drug responses or 
biomarker composition and variations found on the “omics” level (e.g., of genetic polymor-
phisms) or pathogenic variations ( Fig. 3 ). These possibilities justify the establishment of hiPSC 
banks to cover sufficiently large cohorts of patients with renal disease as a resource for disease 
modeling. These models are then applied to verify omics-disease phenotype associations, and 
to test in vitro the associated pathways, including interactions with the complement system. 
We currently use the technology in order to establish hiPSC lines from patients with focal 
segmental glomerulosclerosis, a devastating progressive kidney disease, to analyze patient-
specific phenotypes in hiPSC-derived renal organoids and renal cell types. In addition, we use 
hiPSC-derived renal cells in microfluidic chips to model their response to drug treatments. 
Furthermore, the effect of circulating biomarkers from kidney disease patients on the different 
personalized cell types could be analyzed in such a microfluidics-based perfused system. In the 
other direction, biomarkers secreted by the model cells could easily be analyzed in this perfused 
microfluidics model and directly associated with cell type-specific pathological changes.
 Bioinformatics Tools 
 It is currently very difficult to obtain data on the cell type and single-cell levels, which are 
needed to characterize a cell and, importantly, to assess changes occurring during devel-
opment and pathogenesis. Such depth of characterization is also necessary to unambiguously 
classify hiPSC-derived renal cell types by comparing these cells to their native equivalents. 
Technological tools are now available to characterize cells on the single-cell level and to 
analyze the associated data  [34] . At the BCRT, we have developed a registry of cell type-asso-
ciated data as a first step to characterize most or all distinct cell types of the kidney and other 
organs ( Fig. 3 ). Analytical tools have been developed to compare and classify cells and tissues 
based on their gene expression profiles. Furthermore, we developed a tool for identifying 
tissue- and cell-specific marker genes based on their expression patterns  [35] . Since cell type-
specific reference data are rarely available, especially for native cells of the kidney, we aim at 
generating these data by single-cell RNA sequencing from healthy and diseased tissues.
 In summary, we set up a pipeline starting with generating hiPSCs and differentiating these 
into multiple renal cell types as well as generating 3-dimensional renal organoids in vitro. 
These are being used for disease modeling of focal segmental glomerulosclerosis and other 
renal diseases with the goal to identify the basis of their pathogenic mechanisms and to screen 
for drugs that counter these mechanisms. These approaches are substantiated by bioinfor-
matics tools for cell analysis and by comparison on the molecular and functional levels. The 
cell type-specific data will be used to establish a virtual atlas of the kidney which ranges from 
the molecular to the subanatomical and tissue levels. Finally, we are developing in vitro test 
systems to elucidate regenerative applications of hiPSC-derived cells, and to analyze drugs 
regarding their regenerative and repair potency in kidney models. Eventually, we will apply 
validated cells with a clear mode of action to patients in advanced therapy settings.
 Conclusions 
 Recent data predominantly obtained from animal studies demonstrated a crucial role of 
the complement system in the pathogenesis of AAV. In coincidence with this expanding 
spectrum of complement-mediated diseases, the question arises as to which AAV patients 
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might benefit from complement-targeted therapy. We believe that therapies directed against 
the complement system point to the necessity of a genetic workup of genes of complement 
components and regulators in patients with AAV. Genetic testing, PSCs and bioinformatics 
tools will provide new insights into the pathophysiology of AAVs and may broaden our 
approach to the treatment of patients with aggressive forms of AAV.
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